August 21, 2023 10:00 AM EDTUpdated 11:25 AM
People

The End­points Slack In­ter­view: NewLim­it's Ja­cob Kim­mel brings an­ti-ag­ing back to re­al­i­ty

Andrew Dunn

Senior Biopharma Correspondent

In a field full of ec­centrics, Ja­cob Kim­mel may stand out most for his nor­mal­i­ty.

Kim­mel is a lead­ing an­ti-ag­ing re­searcher who isn’t try­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bris­tol My­ers prunes pipeline amid new round of cost cuts

Pfiz­er hires No­var­tis on­col­o­gy ex­ec to steer its can­cer am­bi­tions

As­traZeneca takes $753M charge on aban­doned com­ple­ment drug from Alex­ion deal

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

J&J, In­tra-Cel­lu­lar quick­ly sealed $14B deal as three oth­ers passed on buy­ing the neu­ro drug­mak­er

Up­dat­ed: Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

A service from the Financial Times